IASLC Awards Heine H. Hansen Lectureship Award for Small Cell Lung Cancer to Stephen V. Liu at the World Conference on Lung Cancer

IASLC Awards Heine H. Hansen Lectureship Award for Small Cell Lung Cancer to Stephen V. Liu at the World Conference on Lung Cancer

Press Release
Aug 05, 2022

­Contact: Chris Martin, IASLC Media Relations, cmartin@davidjamesgroup.com, 630.670.2745

VIENNA, Austria (August 6, 2022) ⎯ Thoracic medical oncologist Stephen V. Liu, MD, was awarded the Heine H. Hansen Lectureship Award for Small Cell Lung Cancer today at the 2022 IASLC World Conference on Lung Cancer.

Dr. Liu is the director of Thoracic Oncology and the Head of Developmental Therapeutics at the Georgetown University Lombardi Comprehensive Cancer Center. He is also an associate professor of Medicine at Georgetown University. His research focuses on rational drug development for lung cancer, and he has authored more than 150 publications. He co-lead the Impower 133 trial that lead to the FDA approval of atezolizumab plus chemotherapy for the first-line treatment of extensive-stage small cell lung cancer -- the first major advance in this disease in decades.

He plays an active role in education, lectures frequently, and has won multiple teaching awards from students and trainees. He is an active member of IASLC, currently serving on the Communications Committee, as well as co-host of the official IASLC podcast, Lung Cancer Considered. 

Dr. Liu received his undergraduate training at Johns Hopkins University, graduating cum laude with a major in Biology and a minor in Film & Media Studies. He earned his medical degree from the University of Maryland and received his Internal Medicine training at the University of Pennsylvania. 

He completed a fellowship in Hematology and Oncology at the University of Southern California School of Medicine and then received further training in drug development and genomic analysis at TGen with Dr. Daniel Von Hoff. 


About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. For more information visit www.iaslc.org.

About the WCLC:

The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2022.iaslc.org/